GE Healthcare, a pharmaceutical and medical equipment manufacturer, has expanded its range of magnetic resonance imaging (MRI) contrast media products with the launch of macrocyclic agent Clariscan (gadoteric acid) in Europe.

Developed to support effective visualisation of abnormalities in the brain, spine and associated tissues, Clariscan is a gadolinium-based contrast agent (GBCA).

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

According to GE Healthcare Life Sciences core imaging general manager Emmanuel Ligner, gadolinium-based agents are an important detection tool in MRI as they provide improved contrast between normal and pathological tissue for rapid detection of abnormalities.

"Clariscan extends GE Healthcare's products and services across MRI, X-ray / CT and ultrasound segments."

Ligner added: “We are therefore pleased to add Clariscan to the family of GE contrast media and imaging products alongside our existing linear agent for MRI, Omniscan, which has been used in routine diagnostic practice for over 25 years with over 80 million administrations.

"We believe macrocyclic Clariscan, manufactured using a proprietary GE process, extends choice for radiology professionals, backed by the well-established quality, reliability and surrounding services GE customers have come to expect.”

See Also:

Available as a suite of doses in vials and pre-filled syringes, Clariscan extends GE Healthcare's products and services across MRI, X-ray / CT and ultrasound segments.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

GE contrast media products are reported to be used in more than 70 million procedures per year.

To enhance its manufacturing capacity, the firm has invested more than $65m in its supply network between 2013 and 2016.

Approved using the decentralised procedure and with marketing authorisation obtained in Norway, the firm intends to launch Clariscan across the countries in Europe throughout this year.